FDA approves tildrakizumab for psoriatic arthritis; half-life extended IL-23 antibody clears skin in 61% in phase 2b

• FDA Oct 30, 2026
  FDA approves tildrakizumab (Ilumya) for adults with active psoriatic arthritis, Sun Pharma says
  The Food and Drug Administration (FDA) approved a supplemental biologics license application for tildrakizumab-asmn (Ilumya), an IL-23 inhibitor already approved for moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, Sun Pharma said Oct. 30. In the phase 3 INSPIRE-1 trial, 61% of tildrakizumab patients achieved ACR20 at week 24 versus 35% on placebo; in INSPIRE-2, the rates were 64% and 33%, according to Dermatology Times. Philip Mease, director of rheumatology research at Swedish Medical Center and Providence St Joseph Health, said a provider-administered IL-23 inhibitor offers a new option.
  Sources: Sun Pharma, Dermatology Times
• Research Oct 26, 2026
  ORKA-001 clears psoriasis completely in 61% of high-dose patients at week 16 in phase 2b EVERLAST-B, Oruka says
  In the phase 2b EVERLAST-B trial of 187 patients with moderate to severe plaque psoriasis, 61% of those receiving 600 mg of ORKA-001, a half-life extended IL-23p19 antibody, achieved PASI 100 at week 16, the primary end point, versus 0% on placebo (P < .0001), according to company-reported interim results released Oct. 26. PASI 90 was reached by 86% in the high-dose group. Oruka said the drug may allow dosing once to twice a year and plans phase 3 trials in the first half of 2027.
  Sources: Oruka Therapeutics, HCPLive, Dermatology Times

The weekly innovation roundup for dermatology, published every Sunday for the week before; every item links to its sources. Latest dermatology news · All specialties